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Abstract: Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro derivative
of avermectin—originating solely from a single microorganism isolated at the Kitasato Intitute,
Tokyo, Japan from Japanese soil—has had an immeasurably beneﬁcial impact in improving the
lives and welfare of billions of people throughout the world. Originally introduced as a veterinary
drug, it kills a wide range of internal and external parasites in commercial livestock and companion
animals. It was quickly discovered to be ideal in combating two of the world’s most devastating and
disﬁguring diseases which have plagued the world’s poor throughout the tropics for centuries. It is
now being used free-of-charge as the sole tool in campaigns to eliminate both diseases globally. It
has also been used to successfully overcome several other human diseases and new uses for it are
continually being found. This paper looks in depth at the events surrounding ivermectin’s passage
from being a huge success in Animal Health into its widespread use in humans, a development which
has led many to describe it as a “wonder” drug.
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Introduction
There are few drugs that can seriously lay claim
to the title of ‘Wonder drug’, penicillin and aspirin
being two that have perhaps had greatest beneﬁcial
impact on the health and wellbeing of Mankind. But
ivermectin can also be considered alongside those
worthy contenders, based on its versatility, safety and
the beneﬁcial impact that it has had, and continues to
have, worldwide—especially on hundreds of millions
of the world’s poorest people. Several extensive
reports, including reviews authored by us, have been
published detailing the events behind the discovery,
development and commercialization of the avermec-
tins and ivermectin (22,23-dihydroavermectin B),
as well as the donation of ivermectin and its use
in combating Onchocerciasis and lymphatic ﬁlaria-
sis.1)–6) However, none have concentrated in detail on
the interacting sequence of events involved in the
passage of the drug into human use.
When it ﬁrst appeared in the late-1970s,
ivermectin, a derivative of avermectin (Fig. 1) was
a truly revolutionary drug, unprecedented in many
ways. It was the world’s ﬁrst endectocide, forerunner
of a completely new class of antiparasitic agents,
potently active against a wide range of internal and
external nematodes and arthropods. In the early-
1970s, a novel international Public Sector–Private
Sector partnership was initiated by one of us
(Ōmura, then head of the Antibiotics Research
Group at Tokyo’s Kitasato Institute), forming a
collaboration with the US-based Merck, Sharp and
Dohme (MSD) pharmaceutical company. Under
the terms of the research agreement, researchers at
the Kitasato Institute isolated organisms from soil
samples and carried out preliminary in vitro evalua-
tion of their bioactivity. Promising bioactive samples
were then sent to the MSD laboratories for further
in vivo testing where a potent and promising novel
bioactivity was found, subsequently identiﬁed as
being caused by a new compound, which was named
‘avermectin’.7) Despite decades of searching around
the world, the Japanese microorganism remains the
only source of avermectin ever found.1) Originating
from a single Japanese soil sample and the outcome of
the innovative, international collaborative research
partnership to ﬁnd new antiparasitics, the extremely
safe and more eﬀective avermectin derivative, iver-
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product for Animal Health in 1981. It is eﬀective
against a wide range of parasites, including gastro-
intestinal roundworms, lungworms, mites, lice and
hornﬂies.7)–12) Ivermectin is also highly eﬀective
against ticks, for example, the ixodid tick Rhipice-
phalus (Boophilus) microplus, one of the most
important cattle parasites in the tropics and sub-
tropics, which causes enormous economic damage.
Indicative of the impact, in Brazil, where some 80%
of the bovine herd is infested, losses total about $2
billion annually.13) Today, ivermectin is being used
to treat billions of livestock and pets around the
world, helping to boost production of food and
leather products, as well as keep billions of com-
panion animals, particularly dogs and horses,
healthy. The ‘Blockbuster’ drug in the Animal
Health sector, meaning that it achieved annual sales
in excess of over US$1 billion, maintained that status
for over 20 years. It is so useful and adaptable that
it is also being used oﬀ-label, sometimes, illegally,
for example to treat ﬁsh lice in the aquaculture
industry, where it can have a negative impact on
non-target organisms. It also has extensive uses in
agriculture.2)
Ivermectin proved to be even more of a ‘Wonder
drug’ in human health, improving the nutrition,
general health and wellbeing of billions of people
worldwide ever since it was ﬁrst used to treat
Onchocerciasis in humans in 1988. It proved ideal
in many ways, being highly eﬀective and broad-
spectrum, safe, well tolerated and could be easily
administered (a single, annual oral dose). It is used to
treat a variety of internal nematode infections,
including Onchocerciasis, Strongyloidiasis, Ascaria-
sis, cutaneous larva migrans, ﬁlariases, Gnathosto-
miasis and Trichuriasis, as well as for oral treatment
of ectoparasitic infections, such as Pediculosis (lice
infestation) and scabies (mite infestation).14) Iver-
mectin is the essential mainstay of two global disease
elimination campaigns that should soon rid the
world of two of its most disﬁguring and devastating
diseases, Onchocerciasis and Lymphatic ﬁlariasis,
which blight the lives of billions of the poor and
disadvantaged throughout the tropics. It is likely
that, throughout the next decade, well over 200
million people will be taking the drug annually or
semi-annually, via innovative globally-coordinated
Mass Drug Administration (MDA) programmes.
Indeed, the discovery, development and deployment
of ivermectin, produced by an unprecedented part-
nership between the Private Sector pharmaceutical
multinational Merck & Co. Inc., and the Public
Sector Kitasato Institute in Tokyo, aided by an
extraordinary coalition of multidisciplinary interna-
tional partners and disease-aﬀected communities, has
been recognized by many experts and observers as one
of the greatest medical accomplishments of the 20th
century.15) In referring to the international eﬀorts
to tackle Onchocerciasis in which ivermectin is now
the sole control tool, the UNESCO World Science
Report concluded, “the progress that has been made
in combating the disease represents one of the most
triumphant public health campaigns ever waged in
the developing world”.16)
Onchocerciasis
The origins of ivermectin as a human drug are
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Fig. 1. Molecular diagrams of avermectin and the di-hydro derivative, ivermectin.
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Blindness), a chronic human ﬁlarial disease caused
by infection with Onchocerca volvulus worms. The
parasites are transmitted via the bite of infected
blackﬂies of the genus Simulium, which breed in
highly-oxygenated, fast-ﬂowing rivers and water-
courses. In the human body, immature larval forms
of the parasite create nodules in subcutaneous tissue,
where they mature into adult worms. After mating,
female worms can release up to 1000 microﬁlariae
a day for some 10–14 years. These move through
the body, and when they die they cause a variety of
conditions, including skin rashes, lesions, intense
itching, oedema and skin depigmentation (Fig. 2).
Microﬁlariae also invade the eye, causing visual
impairment and loss of vision, onchocerciasis being
the second leading cause of blindness caused by an
infectious disease.17) The disease causes visual dam-
age for some 1–2 million people, around half of who
will become blind.18)
In the early-1970s, the disease was endemic in
34 countries: 27 in Africa; 6 in the Americas; and 1 in
the Arabian Peninsula. The World Health Organ-
ization (WHO) later estimated that 17.7 million
people were infected worldwide, of whom some
270,000 were blind, and another 500,000 severely
visually disabled. The burden of onchocerciasis
was particularly extreme in the hyper-endemic belt
across sub-Saharan Africa. Communities in these
areas exhibited high rates of visual disability caused
by Onchocerciasis, up to 40% in some areas, which
caused immeasurable negative impact on individual
and community health, reducing economic capacity
and productivity, and leading to the abandonment of
fertile agricultural lands.19)
By 1973, Onchocerciasis had been recognised
by the then head of the World Bank, Robert
McNamara, as a major disease of massive health
and socioeconomic importance and one in dire need of
combating in West Africa, and he became the key
agent for change. In 1974, following international
recognition of the dramatic consequences of disabling
and disﬁguring Onchocerciasis in Africa, four United
Nations agencies, including the World Bank,
launched the Onchocerciasis Control Programme
in West Africa (OCP). The programme covered 1.2
million km2, protecting 30 million people in 11
countries from River Blindness.
Drug donation
For over a decade, OCP operations were
exclusively based on the spraying of insecticides
by helicopters and aircraft over the breeding sites
of vector blackﬂies in order to kill their larvae.
Following the registration of ivermectin (produced
under the brand name Mectizan®) for human use in
1987, in a hitherto unprecedented move and with
unheralded commitment, Mectizan® was donated by
the manufacturing company, Merck & Co. Inc., to
treat onchocerciasis in all endemic countries for as
long as it was needed. The resultant drug donation
programme was the ﬁrst, largest, longest running and
most successful of all—and proved a model for all
others that have followed. Ivermectin began to be
distributed in 1988, with operations being organized
through the independent Mectizan Donation Pro-
gram (MDP) established and funded by Merck.
Thereafter, OCP control operations changed from
exclusive vector control to larviciding combined with
ivermectin treatment or, in some areas, to ivermectin
treatment alone. Ivermectin swiftly became the drug
of choice for the treatment of Onchocerciasis due
to its unique and potent microﬁlaricidal eﬀects,
the absence of severe side eﬀects and its excellent
safety. It is now the sole tool being used in disease
elimination campaigns in the 16 other African
countries where the disease exists, orchestrated by
Fig. 2. Mali: an old man, blinded by onchocerciasis, with leopard
skin on his legs and nodules on his abdomen. Credit line: WHO/
TDR/Crump.
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(APOC), which commenced operations in 1996. A
single annual dose of 150µg/kg of ivermectin, given
orally, can reduce the level of skin microﬁlariae to
zero and, by interfering with worm embryogenesis,
can delay the build-up of new microﬁlariae for a
period of up to two years. OCP was closed in
December 2002 after virtually stopping disease
transmission in all target nations except Sierra Leone
where operations were hampered by civil war.
The process, from the discovery of ivermectin’s
activity against onchocercal microﬁlariae to the
successful distribution programme from 1988 on-
ward, was neither an easy or direct path. Success was
achieved through groundbreaking and innovative
partnerships. The journey was a complex under-
taking, incorporating scientiﬁc uncertainty, conﬂict-
ing views, ambiguity, frustration, individual innova-
tion and unexpected twists and turns. The actual
discovery of ivermectin was an international team
eﬀort involving a unique, pioneering Public Sector/
Private Sector partnership and the commitment and
vision of several key individuals. Ivermectin’s devel-
opment into a drug for human use also involved a
number of organizational, individual and pharmaco-
logical variables—together with a large slice of luck,
educated insight and personal commitment.
Development of ivermectin for human use
In the mid-1970s, the global community mobi-
lized itself to address the major problems of neglected
tropical diseases. Following the setting up of the
OCP in 1974, the UN-based Special Programme for
Research & Training in Tropical Diseases (TDR) was
established in 1975.20) Onchocerciasis, one of two
ﬁlarial infections among TDR’s eight target diseases,
was at that time a major public health problem
aﬀecting 20–40 million people in endemic areas. At
exactly this time, a specialized novel anthelmintic
mouse screening model in Merck’s research laborato-
ries was identifying the avermectins in the microbial
sample sent by the Kitasato Institute, of which
ivermectin would become the most successful deriv-
ative.
At the time, there were no safe and acceptable
drugs available to treat Onchocerciasis, which had
plagued Africa for centuries, eﬀectively leading to the
creation of the OCP and its vector control focus.
TDR quickly found that, despite many pharmaceut-
ical companies, such as Bayer, Hoﬀman-LaRoche,
CIBA-Geigy and Rhône-Poulenc, carrying out rout-
ing screening for ﬁlaricidal compounds, no companies
were interested in developing suitable anti-Oncho-
cerca drugs, as there was no apparent commercial
market. Worse still, Onchocerca species would not
develop to maturity in any rodents, making it
impossible to screen compounds in an animal model
against the target organism.21) It had been shown
that O. volvulus could infect chimpanzees (Pan
troglodites) but it was deemed unethical to use these
animals for the necessary large-scale research, even
though some testing of compounds was undertak-
en.22),23) Consequently, the OCP opted to devote
operations to aerial larviciding via helicopters and
small ﬁxed-wing planes. It was a very ‘vertical’
programme, mainly coordinated through the World
Bank and other UN agencies, with multimillion
dollar contracts given to a US-based helicopter
company and to an American chemical company for
the insecticides.
Meanwhile, with respect to research needs, TDR
had identiﬁed six speciﬁc areas that required special
attention, with the discovery of eﬀective and safe
chemotherapeutic agents considered to be the highest
priority. In 1975, only two drugs were available for
the treatment of onchocerciasis: diethylcarbamazine
(DEC) and suramin. The use of both was highly
unsatisfactory. DEC, which was known to kill
microﬁlariae, caused violent and even dangerous
hypersensitivity reactions in the human host. Sur-
amin, developed 50 years previously for treatment
of Sleeping Sickness, was the only drug considered
for killing adult worms but was highly toxic, often
causing severe and occasionally fatal reactions.
Moreover, parasitological cure of patients using
DEC and suramin required lengthy and expensive
treatment given under medical supervision. There-
fore, the TDR Scientiﬁc Working Group (SWG),
composed of leading independent scientists in the
ﬁeld from around the globe, including industry,
decided that the priority was a new and non-toxic
macroﬁlaricide (to kill adult worms), a macroﬁlar-
icide being determined to be substantially preferable
to a microﬁlaricide (which would target immature
worms).24)
At the ﬁrst meeting of TDR’s Filariasis Scientiﬁc
Steering Committee in 1976, it was reported that
Programme staﬀ had visited 16 major pharmaceut-
ical companies but had found none actively working
on onchocerciasis. Nor was there any validated model
for screening. The Committee agreed that the high
cost of maintaining screening facilities for drugs
against tropical diseases was a signiﬁcant deterrent
to industrial involvement.25) TDR acted to rectify
A. CRUMP and S. ŌMURA [Vol. 87, 16this situation and thereby engage industry in the
search for a new drug. Unfortunately, O. volvulus
parasites can only develop fully in humans and a few
primates. Fortunately, the closest relative to the
human parasite is O. ochengi, found in cattle, which
is restricted to Africa and which is also transmitted
by the same vector. The O. ochengi cattle model
thus facilitated experimental studies, in the ﬁeld and
laboratory-based, that were not possible in humans,
leading to detailed knowledge of the parasite’s life
cycle (Fig. 3). From 1977 on, TDR provided techni-
cal and ﬁnancial support to establish a comprehen-
sive screening system for Onchocercal ﬁlaricides.
The Programme identiﬁed ﬁve academic and private
research institutions with technical capacities and
facilities for primary and secondary screens: the
University of Georgia (USA), University of Giessen
(Germany), the Wellcome Foundation (UK), the
London School of Hygiene and Tropical Medicine
(UK) and the University of Tokyo (Japan). TDR
provided some US$2.25 million to these Public Sector
institutions for primary and secondary screening of
compounds, while pressing pharmaceutical compa-
nies to donate compounds for testing with the
promise of full conﬁdentiality. Additionally, TDR
established a unique tertiary screen, using cattle, for
compounds showing positive results in any secondary
screen. Based at the James Cook University of
North Queensland, Australia, the screen, costing
almost US$435,000, was the best predictor of what
a compound would do in humans. Some 10,000
compounds, many supplied by leading pharmaceut-
ical companies as coded samples, passed through
the screening network, including several from
Merck.26)
In reality, ivermectin’s role in human medicine
eﬀectively began in April 1978 inside the Merck
company, several years before the drug emerged
Human host stages
Simulium blackfly stages
1 L3 larvae enter human skin when 
a female fly takes a blood meal
2 Larvae migrate to subcutaneous tissue
develop into adults and form nodules
(mature in 6-12 months)
3
Adult females produce unsheathed
microﬁlariae (around 1,000/day) that 
migrate into the skin and connective tissue 
lymphatics, as well as into peripheral blood
4
Microfilariae migrate to the skin 
during the day when blackflies 
ingest them in the bloodmeal
5
Microﬁlariae shed sheaths,
penetrate midgut and migrate 
to thoracic muscles 
6 Larval stages (L1 and L2)
7 L3 Larvae
8 L3 larvae migrate to head,
proboscis and saliva 
(mature in 7 days)
Fig. 3. Life cycle of Onchocerca volvulus.
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bioactivity of a fermentation broth of an organism
isolated by the Kitasato Institute in Tokyo, which
had been sent to Merck’s research laboratories
in 1974, was ﬁrst identiﬁed in 1975. The active
compounds were identiﬁed by the international
multidisciplinary collaborative team as the avermec-
tins, with the subsequently-reﬁned ivermectin deriv-
ative being designated the optimal compound for
development. Merck scientists, under the direction of
Dr William Campbell, found that the drug was active
against a wide range of parasites of livestock and
companion animals.10) The informed foresight of a
Merck researcher, Ms. L.S. Blair, resulted in the
discovery that the drug was eﬀective against skin-
dwelling microﬁlariae of Onchocerca cervicalis in
horses. These did not actually cause clinical disease
and so the ﬁnding was of little commercial signiﬁ-
cance. However, O. cervicalis belongs to the same
genus as O. volvulus, and upon reading the exper-
imental reports, Dr Campbell surmised that there
might be some merit in testing for impact against
the latter. In July 1978, he sent ivermectin (as a
coded sample), together with the results of the horse
trial, to the TDR-supported tertiary cattle screen
in Australia. The results, obtained in November
1978, showed that ivermectin was “highly eﬀective
in preventing patent infections with both O. gibsoni
and O. gutturosa”. This reinforced Campbell’s grow-
ing belief that ivermectin would be eﬀective against
human onchocerciasis. Consequently, in December,
he proposed to the Merck Laboratories’ Research
Management Council that “an avermectin could
become the ﬁrst means of preventing the blindness
associated with onchocerciasis” and that “discussions
be held with representatives of WHO to determine
the most appropriate approach to the problem—
from the medical, political and commercial points of
view”.27),28) Senior management approved the lead
taken by Campbell and research funding to inves-
tigate the potential use of ivermectin in humans was
approved by Dr Roy Vagelos, then President of the
research laboratories.
TDR reactions to the initial data about iver-
mectin were rather muted, especially as it was
searching for a macroﬁlaricide and ivermectin ap-
peared to have little impact on adult worms. In late-
1979, a TDR oﬃcial visited Merck and, although the
meeting resulted in TDR’s technical contribution to
Merck’s ivermectin research, there was no ensuing
discussion about collaboration to develop ivermectin
for use in human Onchocerciasis.
Fortunately for all, in January 1980, Merck
decided to proceed independently to Phase I (safety)
trials. Clinical trials of ivermectin began in 1981, with
a Phase I trial in 32 patients in Senegal followed
by another trial in Paris among 20 West African
immigrants. These trials were independently organ-
ized and funded by Merck, with a staﬀ member, Dr
Mohamed Aziz, previously of WHO, being the caring
and committed driving force behind them. Dr Aziz
started the study in Senegal with safety uppermost
in his mind. It began with a very low dose of 5µg/kg
and found that a single dose of ivermectin, 30µg/kg,
substantially decreased the number of skin micro-
ﬁlariae. It also established that the eﬀect lasted for at
least 6 months, with no serious adverse events being
observed. The subsequent Paris study conﬁrmed
these results and showed that doses up to 200µg/kg
were well tolerated.29),30)
When Merck oﬃcials visited TDR and OCP in
1982 to present the results from the Phase I trials,
each side recognised the immense potential and
collaboration in earnest began.
Evidence suggests that collaboration between
these major partners commenced in a complex
environment of mutual wariness, suspicion and
shared hope that ivermectin would indeed prove to
be an eﬀective treatment for Onchocerciasis. The
situation was compounded by the fact that Merck
saw ivermectin as a potentially commercial product
to be used for individual patient treatment, and
moved forward constantly seeking an income return
on its investment. In contrast, TDR, together with
OCP, saw the drug as a new community-level tool
that could possibly interrupt parasite transmission
and thereby help reduce the prevalence of the disease
in endemic communities. TDR and OCP conse-
quently regarded community-based trials under ﬁeld
conditions as an essential step towards mass-treat-
ment programmes, as opposed to the individual
treatment in hospitals favoured by the commercial
partner. The continual negotiation with respect to
the cost of the drug eventually resulted in a commit-
ment from Merck in July 1985 to supply it in
suﬃcient quantities and at the lowest possible price
consistent with the interests of the company, later
conﬁrming that it would be made available to
“+ governments and patients at no cost to them
for the treatment of Onchocerciasis”.31)
With respect to oﬃcial registration of ivermectin
for human use, Merck, focussing on the single-patient
approach, pressed ahead on its own and submitted
an application to the French health authorities in
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onchocerciasis patients, expecting to receive approval
later that year, which it subsequently did.24),32) In its
submission, Merck indicated a price of $3 per tablet,
meaning that a treatment dose would cost $6, well
beyond an aﬀordable amount for those most in need.
Prior to registration, the involvement of TDR
and OCP increased substantially, as they organised
ﬁeld trials, including extremely expensive, large-scale
trials of the eﬀectiveness of ivermectin in community
treatment programmes, and campaigned tirelessly to
get the cost of treatment reduced to an acceptable
level. During the trials to test the eﬃcacy of the drug
in ﬁeld settings (Phase II trials starting in 1983),
Merck continued to fund much of the work, with
additional ﬁnancial support from OCP and TDR.
Fortunately, TDR’s existing international network
facilitated Merck’s ability to develop workable
relationships with researchers and institutions to
conduct activities in Africa and South America.
TDR was also able to inﬂuence the design of study
protocols, and support applied research on oncho-
cerciasis treatment at one of its specialized centres,
the Onchocerciasis Chemotherapy Research Centre
(OCRC) in Tamale, Ghana, where Dr Kwable
Awadzi had devised a method to quantify clinical
reactions to microﬁlaricides using a scoring system of
commonly observed reactions.33) This made it possi-
ble to compare the degrees of systemic reactions for
all compounds using a common metric, eventually
conﬁrming the promise of ivermectin as a safe and
highly eﬀective microﬁlaricide.
Thirteen community-level (Phase IV) trials were
conducted between 1987–1989, with over 120,000
individual doses of ivermectin administered. Of the
13 community trials, TDR funded ﬁve in Liberia,
Cameroon, Malawi, Guatemala and Nigeria, and
spent US$2.35 million in total. Over the period,
TDR spent between 25–35% of its total annual budget
for all ﬁlariasis work on ivermectin. OCP funded the
eight other studies in Ghana, Mali, Togo, Benin, Ivory
Coast, Guinea, Burkina Faso and Senegal. As a
private sector company, Merck’s ﬁnancial contribu-
tions to the development of ivermectin for human use,
although substantial, remain unknown.
Advantages of ivermectin for treating
Onchocerciasis
Ivermectin proved to be virtually purpose-built
to combat Onchocerciasis, which has two main
manifestations, dermal damage resulting from micro-
ﬁlariae in the skin and ocular damage arising from
microﬁlariae in the eye. Until the advent of ivermec-
tin, despite its drawbacks, DEC was the drug of
choice traditionally used to treat patients with
onchocercal infection. DEC acts quickly to eliminate
microﬁlariae from the anterior chamber of the eye
and keeps the eye clear for a year or more. However,
the rapidity of clearance often causes ocular damage
as a result of an exaggerated inﬂammatory reaction.
Conversely, ivermectin proved to slightly increase
microﬁlariae in the eye upon treatment, followed by a
gradual reduction, reaching to near zero, similar to
DEC, within six months (Fig. 4). Most signiﬁcantly,
little or no resultant ocular damage occurs. Unlike
DEC, it is believed that the large molecular size of
ivemectin, a macrocylic lactone, prevents it from
crossing the blood/aqueous humour barrier, stopping
it entering the anterior chamber and exerting an
eﬀect directly on microﬁlariae.34) This makes iver-
mectin an ideal treatment for patients with ocular
involvement.
Similarly, evaluation of the impact of DEC and
ivermectin on dermal microﬁlariae, conﬁrmed that
both caused almost complete clearance within two
days after treatment, reducing the load to virtually
zero within eight days. However, although both drugs
produce long-term suppression of the reappearance
of microﬁlariae, ivermectin is superior, virtually
eliminating all microﬁlariae and maintaining that
status for some 90 days, whereas the eﬀect of DEC
wanes after little more than a week (Fig. 5). Thus,
ivermectin is also an ideal treatment for dermal
involvement.35) In addition to being perfectly tailor-
made for Onchocerciasis, ivermectin has progressed
to become a ‘wonder drug’ for other diseases too.
Eﬀectiveness against other ﬁlarial diseases
Lymphatic Filariasis, also known as Elephantia-
sis, is another devastating, highly debilitating disease
that threatens over 1 billion people in more than 80
countries. Over 120 million people are infected, 40
million of whom are seriously incapacitated and
disﬁgured. The disease results from infection with
ﬁlarial worms, Wuchereria bancrofti, Brugia malayi
or B. timori. The parasites are transmitted to
humans through the bite of an infected mosquito
and develop into adult worms in the lymphatic
vessels, causing severe damage and swelling (lym-
phoedema) (Fig. 6). Adult worms are responsible for
the major disease manifestations, the most outwardly
visible forms being painful, disﬁguring swelling of the
legs and genital organs (Fig. 7). The psychological
and social stigma associated with the disease are
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it causes.
With respect to the use of ivermectin for
Lymphatic ﬁlariasis, again Merck took the initial
lead, with TDR being involved in organising,
expanding and broadening the research and clinical
trials. In the mid-1980s, well before ivermectin was
approved for human use to treat onchocerciasis,
Merck were also undertaking trials of ivermectin to
measure its impact against lymphatic ﬁlariasis and to
ﬁnd optimal treatment dosages.36) Meanwhile, TDR
was carrying out multi-centre ﬁeld trials in Brazil,
China, Haiti, India, Indonesia, Malaysia, Papua New
Guinea, Sri Lanka and Tahiti to evaluate ivermectin,
% of pre-treatment value
Day
After Lariviere, et.al. (1985)
Fig. 5. Eﬀect of ivermectin and diethylcarbamazine (DEC) on microﬁlariae in the skin.
Geometric mean 
microfilariae
Day
After Dadzie, et. al. (1987)
Fig. 4. Eﬀect of ivermectin and diethylcarbamazine (DEC) on microﬁlariae in the Anterior Chamber of the eye.
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of the two. The results showed that single-dose
ivermectin and single-dose DEC worked as well as
each other. The combination, even at low dose,
proved even more eﬀective, decreasing microﬁlarial
density by 99% after one year and 96% after two
years.20),37)–39) DEC was also found to be eﬀective in
killing adult parasites.
Despite these ﬁndings, ivermectin remained
unregistered for treatment of lymphatic ﬁlariasis
for several years. Indeed it was not until 1998
that registration was forthcoming from the French
authorities. Several years earlier another drug,
albendazole, produced by SmithKlineBeecham (now
GlaxoSmithKline – GSK) had also been shown to be
eﬀective in killing both immature and adult worms.
Indeed, ﬁeld trials had conﬁrmed that once-yearly
combinations of albendazole plus DEC or ivermectin
were 99% eﬀective in ridding the blood of micro-
ﬁlariae for at least a year after treatment. The
primary goal of treating aﬀected communities thus
became elimination of microﬁlariae from the blood of
infected individuals so that transmission of infection
is interrupted. This opened up the prospect of
actually eliminating the disease, something that was
made eminently possible thanks to GSK agreeing
to donate albendazole. In 1997, following advances
in both diagnosis and treatment, WHO classiﬁed
lymphatic ﬁlariasis as one of six “eradicable” or
“potentially eradicable” infectious diseases and re-
quested Member States to initiate steps to eliminate
lymphatic ﬁlariasis as a public health problem.40) In
late-1998, following registration of the drug for
lymphatic ﬁlariasis, Merck extended its ivermectin
donation programme to cover lymphatic ﬁlariasis in
areas where it co-existed with Onchocerciasis. Sub-
sequently, in 1999/2000, the WHO launched the
Global Programme to Eliminate Lymphatic Filariasis
(GPELF).
In summary, the vision of ivermectin as a
potential drug for human onchocerciasis emanated
from Merck’s research team. TDR facilitated the
Fig. 6. Life cycle of Wuchereria bancrofti.
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of the lack of an eﬀective tool to identify potential
anti-Onchocerca ﬁlaricides, its proactive engagement
with pharmaceutical companies; its creation of and
funding for animal model and screening systems; and
by mobilizing and engaging its international network
of researchers and institutions. TDR’s unique posi-
tion as an international body with a mandate to
coordinate research work and provide funds in
tropical diseases facilitated and made possible the
passage of Merck’s compound through to ﬁeld use in
Africa and elsewhere, allowing the foresight of Merck
scientists and the enormous resources devoted by the
company to result in immeasurable public health
beneﬁts.
Mode of action
Initially, researchers working on the develop-
ment of ivermectin believed that it blocked neuro-
transmitters, acting on GABA-gated Cl! channels,
exhibiting potent disruption at GABA receptors in
invertebrates and mammals. GABA is recognised
as the primary inhibitory neurotransmitter in the
somatic neuromuscular system of nematodes. Sub-
sequently, they discovered that it was in fact
glutamate-gated Cl! channels (GUCl!) that were
the target of ivermectin and related drugs. This
discovery opened up a completely new spectrum
of possibilities, as these channels, although playing
fundamental roles in nematodes and insects, are not
accessible in vertebrates.41)–43) Ivermectin, while
paralyzing body-wall and pharyngeal muscle in
nematodes has no such impact in mammals, as it
cannot cross the blood-brain barrier into the mam-
malian Central Nervous System, where GABA
receptors are located. For a long time, it was believed
that ivermectin was contra-indicated in children
under the age of ﬁve or who weighed less than 5kg,
as there was a fear of neurotoxicity, the drug possibly
being able to cross the as yet not fully developed
blood/brain barrier. However, evidence has emerged
that is probably not the case.44)
In the human body, ivermectin exerts a peculiar
and singular eﬀect that remains poorly understood.
The immune response to ﬁlarial infection is complex,
involving Th2-type systems which counter infective
L3 larvae and microﬁlariae, whereas a combination
of Th1 and Th2 pathways are involved in resisting
adult worms. It is believed that female adult worms
are able to manipulate the immunoregulatory envi-
ronment, possibly via interleukin 10 (IL-10) levels, to
ensure the survival of their microﬁlarial oﬀspring.45)
Ivermectin treatment of Onchocercal ﬁlarial infection
causes the disappearance of microﬁlariae from the
peripheral skin lymphatics. It does so relatively
quickly and with long-lasting eﬀect, while also
inhibiting adult female worms from releasing addi-
tional microﬁlariae.46) Dermal microﬁlarial loads are
generally reduced by 78% within two days, and by
some 98% two weeks after treatment. They remain
at extremely low levels for about 12 months, with
70% of female worms slowly resuming production of
microﬁlaria 3–4 months after treatment, but at an
irreversibly curtailed 35% of original production.47)
Regular treatment consequently decreases incidence
of infection, interrupts transmission and reduces
morbidity and disability. However, the actual mech-
anism by which ivermectin exerts its eﬀect on
Onchocercal microﬁlariae remains unclear.48) In
binding to GUCl!, ivermectin disrupts neurotrans-
mission that is regulated via these channels in
nematodes. But in culture, the drug has little direct
eﬀect on microﬁlariae when administered at pharma-
cologically relevant concentrations. It is now believed
that the drug actually disrupts the fundamental host-
Fig. 7. Ghana: an old man co-infected with onchocerciasis and
lymphatic ﬁlariasis. He is partially sighted, with a worm nodule
on his right leg and leopard skin on his left leg. He also displays
elephantiasis of the left leg and has a large hydrocele. Credit line:
WHO/TDR/Crump.
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in humans is 12–36 hours, while metabolites may
persist for up to three days. As lowest levels of
dermal microﬁlariae occur well after this timeframe,
it suggests that not all microﬁlariae aﬀected by
ivermectin are killed in the ﬁrst few days. This is
augmented by reports that microﬁlariae migrate into
deeper dermal layers, sub-cutaneous fat, connective
tissue and lymph nodes following administration
of the drug.49) The prevailing school of thought is
that ivermectin actually interferes with the ability of
microﬁlariae to evade the human immune system,
resulting in the host’s own immune response being
able to overcome the immature worms and so kill
them.50) Recently published research has indicated
that GUCl! activity is solely expressed in muscu-
lature surrounding the microﬁlarial excretory–secre-
tory (ES) vesicle, suggesting that any compound
originating from the ES vesicle is regulated by the
activity. The addition of ivermectin markedly re-
duces the amount of a protein (which is postulated
to play a role in helping the parasite elude the host’s
immune system) that is released from the ES in
microﬁlariae.51) The growing body of evidence sup-
ports the theory that the rapid microﬁlarial clearance
following ivermectin treatment results not from
the direct impact of the drug but via suppression of
the ability of the parasite to secrete proteins that
enable it to evade the host’s natural immune defence
mechanism.
Animal models have indicated conclusively that
Th2 responses instil protective immunity against
both L3 infective larvae and the microﬁlaria stage
but that parasites are generally able to avoid these
responses. This indicates that development of an
eﬀective vaccine may be possible, once a more
comprehensive understanding of the process has been
established.52) This overview may help explain the
absence or comparatively slow development of drug
resistance in the parasites in individuals, many of
whom have been exposed to over 20 years of regular
ivermectin treatment.
Drug resistance
Soon after its use became widespread in animal
health, ivermectin resistance began to appear, at
ﬁrst in small ruminants but also, more signiﬁcantly
in cattle parasites, especially Cooperia spp.53) It is
well known that high-level resistance to ivermectin
appears in free-living Caenorhabditis elegans.54)
Thankfully, despite 30 years of constant worldwide
use, there have been no reports of resistance in canine
heartworms or among equine Strongyloides parasites.
More importantly, despite some 22 years of constant
monotherapy in humans, no convincing evidence of
resistance in Onchocerca volvulus has yet been found,
although there are indications that resistance may be
starting to develop and that resistant parasites are
being selected.55),56)
New horizons
Ivermectin has continually proved to be aston-
ishingly safe for human use. Indeed, it is such a
safe drug, with minimal side eﬀects, that it can be
administered by non-medical staﬀ and even illiterate
individuals in remote rural communities, provided
that they have had some very basic, appropriate
training. This fact has helped contribute to the
unsurpassed beneﬁcial impact that the drug has
had on human health and welfare around the globe,
especially with regard to the campaign to ﬁght
Onchocerciasis.57)
Today, ivermectin is being increasingly used
worldwide to combat other diseases in humans,
such as Strongyloidiasis (which infects some 35
million each year), scabies (which causes 300 million
cases annually), Pediculosis, Gnathostomiasis and
Myiasis—and new and promising properties and uses
for ivermectin and other avermectin derivatives
are continuing to be found.58) These include
activity against another neglected tropical disease,
Leishmaniasis.59),60) Of perhaps even greater signiﬁ-
cance is the evidence that the use of ivermectin has
both direct and indirect beneﬁcial impact on improv-
ing community health. Studies of long-term treat-
ment with ivermectin to control Onchocerciasis have
shown that use of the drug is additionally associated
with signiﬁcant reduction in the prevalence of
infection with any soil-transmitted helminth para-
sites (including Ascaris, Trichuris and hookworm),
most or all of which are deemed to be major causes of
the morbidity arising from poor childhood nutrition
and growth.61) It is also known that the prevalence
of head lice is markedly reduced in children taking
ivermectin tablets62) and that scabies is markedly
reduced in populations taking the drug regularly.63)
Above all, ivermectin has proved to be a medicine of
choice for the world’s rural poor. In many under-
privileged communities throughout the tropics,
intestinal worms and parasitic skin diseases are
extremely common and associated with signiﬁcant
morbidity. They usually co-exist, with many individ-
uals infected with both ecto- and endoparasites.64),65)
Mass treatment of poly-parasitized populations is
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ivermectin is the ideal drug for such interventions.
A recent study in Brazil, using locally produced
ivermectin, looked at the impact on internal
helminthes and parasitic skin diseases. The research-
ers concluded that “mass treatment with ivermectin
was an eﬀective and safe means of reducing the
prevalence of most of the parasitic diseases prevalent
in a poor community in North-East Brazil. The
eﬀects of treatment lasted for a prolonged period of
time”. This study also represented the ﬁrst published
report of human medical intervention using ivermec-
tin that had not been produced by the hitherto
traditional manufacturer, Merck & Co. Inc., the
patent on the drug expiring in 1997.66)
In reality, the renewed interest in ﬁghting
tropical diseases, including the involvement of the
pharmaceutical industry, which has become increas-
ingly evident over the past three decades, and which
has saved lives and improved the welfare of billions
of people, notably the poor and disadvantaged in the
topics, can be traced back to the 1987 introduction of
ivermectin for use in humans. According to a recent
report, International Federation of Pharmaceutical
Manufacturers & Associations (IFPMA) data show
that the global pharmaceutical industry provided
over $9.2 billion in health interventions (medicines
and equipment) between 2000–2007 alone, beneﬁt-
ting 1.75 billion people worldwide.67) The hitherto
unprecedented donation of ivermectin in 1987 can
rightly be seen to be the origin of this philanthropic
outpouring.
Since the inception of the Mectizan Donation
Programme, Merck has donated well over 2.5 billion
Mectizan® tablets for Onchocerciasis treatment,
with in excess of 700 million treatments authorised.
Currently, some 80–90 million people are taking
the drug annually through MDA in Africa, Latin
America and Yemen. A further 300 million total
treatments have been approved for lymphatic ﬁlar-
iasis, with around 90 million treatments being
administered annually (Fig. 8). At present 33 coun-
tries are receiving ivermectin for Onchocerciasis and
15 for Lymphatic ﬁlariasis. Consequently, around
US$4 billion worth of ivermectin tablets have been
donated to date. In 2010, Ecuador became the second
country in the Americas to halt River Blindness
transmission. It is hoped that transmission of the
disease in the Western hemisphere will be stopped by
2012—a goal that will have been achieved thanks to
twice-yearly MDA with ivermectin. Lymphatic ﬁlar-
iasis is targeted for global elimination by 2020, and, if
all goes well, Onchocerciasis may well be eliminated
from Africa soon thereafter.
It has, thus far, been a long and eventful journey
from ivermectin’s origins in Japanese soil. Fortu-
nately, and contrary to the position seen with most
antibiotics, despite several decades of monotherapy
Million
Year
Data sources: Mectizan Donation Program; Merck & Co. Inc.
Fig. 8. Trend in ivermectin treatments approved (1988–2008).
A. CRUMP and S. ŌMURA [Vol. 87, 24and occasional suboptimal responses observed in
some individuals, there is no conclusive evidence
that drug resistance is developing in human Oncho-
cercal parasites. Not surprisingly, public health
specialists worldwide are now calling for greater
and more extensive use of ivermectin,68) labelling
MDA of the ‘wonder drug’ quite simply as “an
underutilized public health strategy”. In response, the
Kitasato Institute has initiated a global collaboration
to investigate all properties and potential of a range
of ivermectin analogues, both individually and in
combination, particularly with a view to having a
ready-made alternative should resistance to current
ivermectin monotherapy ever threaten ongoing dis-
ease elimination campaigns.
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